

INDEX

Note: AF stands for atrial fibrillation.

Page numbers in *italics* indicate figures.

Page numbers followed by a “t” indicate tables.

Clinical trials and studies are indexed under the acronym of the name.

- A to Z Trial, 93
- AADs. See *Antiarrhythmic drugs (AADs)*.
- Ablation. See also *Catheter ablation; Surgical ablation*.
 - catheter ablation, 162-180
 - clinical studies, 116t-117t
 - with pacemaker implantation, 267-269, 275-276
 - partial, 269
 - surgical ablation, 180-187, 267-269
- ACC/AHA/ESC Guidelines
 - AAD initiation, 210, 211t
 - AF classification, 17-21
 - anticoagulation, 290-291, 292t
 - catheter ablation, 179, 180, 182-183
 - device guidelines, 101-102
 - diagnostic tests, 70t-71t
 - electrical cardioversion, 132-133, 146
 - pharmacologic cardioversion, 151, 152, 152t
- ACE inhibitors, 86-91, 87, 88t, 102, 299
 - in combination with AADs, 211-212
- Acetazolol, 256t
- Acetaminophen, 312t
- Acetylcholine, 39
- ACT I-IV trials, 160-161
- Action potentials
 - in atria vs ventricles, 153-158, 158
 - prolongation of, 195
- ACTIVE-A study, 328
- ACTIVE-W trial, 303-304, 328
- Acute decompensated heart failure (ADHF), 63
- ACUTE trial, 331-332
- ACUTE II study, 332
- Adenosine, 55, 196
- ADONIS, 222-223, 229
- AF-CHF trial, 120, 124-125
- AF Symptoms Study, 269
- AFASAK, 298-300, 302
- AFFECTS Registry, 304
- AFFIRM trial, 31, 114-122, 116t-117t, 119, 124, 126, 192, 212, 217-218, 250-251, 261, 267
- African Americans, 27, 83
- Age, 23-24, 24, 26, 59. See also *Elderly patients; Young patients*.
 - AAD risk and, 150
 - atrial changes with, 47
 - cardioversion and, 132
 - catheter ablation risks and, 170
 - thromboembolic risk and, 285, 292t, 293t
- Aggrastat to Zocor (A to Z) Trial, 93
- Albuterol, 55
- Alcohol intake, 54-55, 314
- Aldosterone, 42

- Aldosterone antagonists, 86, 88t, 91
- Allopurinol, 313t
- Ambulatory arrhythmia monitoring, 75, 77-78, 79t
- American Academy of Family Physicians and American College of Physicians guidelines, 126
- American College of Cardiology. See *ACC/AHA/ESC Guidelines*.
- American Heart Association. See *ACC/AHA/ESC Guidelines*.
- Amiodarone, 157t, 205t, 213-219
 - action mechanism, 205t, 213
 - adverse effects, 157t, 196, 198, 205t, 215-216, 263
 - captisol-based formulation (Nexterone), 214
 - clinical studies, 116t-117t, 217-219
 - contraindications/cautions, 208, 216
 - derivative of. See *Dronedarone*.
 - dosing, 205t, 214-215
 - drug/device interactions, 157t, 216-217, 234, 240, 260, 263, 312t, 317
 - implanted device threshold effects, 197t
 - indications for, 274
 - cardioversion
 - failed electrical, 146-147, 146t, 147t
 - pharmacologic, 151, 152, 152t, 157t
 - repeat electrical, 143, 143t, 144, 144t
 - decompensated heart failure, 272
 - maintenance of NSR, 203, 205t, 207, 213-219
 - rate control, 150, 262-263, 271-272, 275, 276
 - underlying heart disease and, 182-183
 - initiation of therapy, 211t
 - monitoring, 199, 200t-201t, 216
 - pharmacokinetics, 213
 - safety of, 146, 198
- Amoxicillin/clavulanate, 312t
- Amplatzer Cardiac Plug, 342, 343, 347
- Anabolic steroids, 313t
- ANDROMEDA, 223-224
- Anesthesia, for electrical cardioversion, 133-134, 141
- Angina, 64
- Angiotensin-converting enzyme inhibitors. See *ACE inhibitors*.
- Angiotensin I receptor signaling, 91
- Angiotensin II, 38, 43
 - receptor activation, 38
 - receptor blockade, 86-91, 87, 88t
- Angiotensin receptor blockers (ARBs), 86-91, 87, 88t, 299
 - in combination with AADs, 211-212
- ANP (atrial natriuretic peptide), 42, 58
- Anti-inflammatory agents, 86, 91, 310-311, 312t
- Antiarrhythmic drugs (AADs), 191-248
 - action mechanisms, 202, 204t-205t
 - agents available, with detailed parameters, 213-244
 - anticoagulation and, 212, 262
 - atrial selective, 153-162, 161, 163t
 - cardioversion and
 - electrical cardioversion
 - failed, 146-147, 146t, 147t
 - repeat, 143-144, 143t, 144t
 - pharmacologic cardioversion with, 148-149, 154t-157t
 - choice of AADs for, 152-153, 152t, 153t
 - new (atrial selective) AADs, 153-162, 161, 163t
 - Antiarrhythmic drugs (AADs) (*continued*)
 - choice of, 202-209, 204t-205t
 - algorithm/stepwise approach, 206
 - available agents, 213-244
 - guidelines and recommendations, 203, 207
 - heart failure patients, 209
 - hypertensive patients, 208
 - patients with coronary artery disease, 208-209
 - patients with no or minimal heart disease, 203-208
 - for pharmacologic cardioversion, 152-153, 152t, 153t
 - classification (Vaughan-Williams), 204t-205t
 - clinical trials, 114-125, 116t-117t
 - combination therapy, 211-212
 - contraindications/cautions, 150, 154t-157t
 - drug interactions, 154t-157t
 - efficacy, 113-125, 116t-117t, 192-193
 - ESC Guidelines, 180, 182-183
 - initiation of therapy, 209-211, 275
 - hospitalization requirements for, 211t
 - for maintenance of NSR, 191-248, 204t-205t
 - agents available, 213-244
 - efficacy, 192-193
 - goals of therapy, 191
 - indications for, 192
 - principles of therapy, 191-198
 - safety considerations, 193-197
 - stepwise approach, 206
 - monitoring, 198-202, 200t-201t
 - outpatient use of, 150, 210-211
 - for rate control, 262-264, 275, 276
 - safety considerations, 113-114, 193-197
 - AF conversion to atrial flutter, 150, 195-196
 - atrial remodeling and, 149
 - hemodynamic effects, 197-198
 - implanted device function, 197, 197t
 - organ toxicity, 198
 - proarrhythmias, 150, 158, 193-197
 - toxicity, 148, 150
 - side effects, 151, 154t-157t, 163t, 193
 - potentially lethal, 193
 - vs catheter ablation, 174-179, 176t-178t, 179
- Antibiotics, 196t, 311, 312t
- Anticoagulation therapy, 298-315. See also *Warfarin*.
 - bridging therapy, 340
 - with cardioversion procedures, 132, 134-135, 149-150, 328-334, 336-337
 - AF duration and, 329-330, 336-337
 - prevention of new thrombus, 333-334, 333
 - risk of preexisting thrombus, 330-333
 - with catheter ablation, 169
 - interruption of, in AF patients, 339
 - long-term continuation of, 119-120, 127, 337
 - newer anticoagulants, 315-325
 - advantages and disadvantages, 326t
 - direct thrombin inhibitors, 299, 316-322
 - factor Xa inhibitors, 299, 322-325
 - special situations
 - AF ablation and Cox-Maze procedure, 169, 334
 - AF due to reversible causes, 338-339

Anticoagulation therapy, special situations (*continued*)

- AF patients presenting with stroke, 334-335
- atrial flutter, 335-338
- bleeding risk, decreasing, 340-341
- cardioversion procedures, 132, 328-334, 336-337
- interruption of anticoagulation in AF patients, 339
- patients with coronary interventions, 339-341
- warfarin interruption, 340
 - for stroke prevention, 290-291, 292t, 298-315, 299
- Antidepressants, 196t
- Antifungal agents, 196t, 221
- Antihistamines, 196t, 341
- Antihypertensive agents, 299
- Antimicrobial drugs, 196t
- Antimotility drugs, 196t
- Antioxidants, 99-100
- Antiplatelet therapy, 325-328
 - bleeding risk, decreasing, 340-341
 - combination of agents, 328
 - drug interactions, 312t
 - for stroke prevention, 297, 299
 - vs warfarin, 302-304
- Antithrombotic therapy, 111, 279-352. See also *Thromboembolism*.
- Antithyroid drugs, 313t
- Antiviral agents, 196t, 312t
- Anxiety, differential diagnosis of, 65
- Aortic stenosis, 63, 66
- Apixaban, 299, 322, 324-325
- ARBs (angiotensin receptor blockers), 86-91, 87, 88t, 102, 299
 - in combination with AADs, 211-212
- ARISTOTLE study, 325
- ARMYDA3 trial, 92, 93, 96
- Arrhythmias, related, 16-17, 17, 46t
- Asians, 27
- Aspirin, 327-328
 - bleeding risk, decreasing, 340-341
 - interaction with warfarin, 310, 312t
 - SPAF III trial, 301-302
 - for stroke prevention, 290-291, 292t, 297, 299, 327-328
 - combination therapy, 328
 - triple therapy, 339, 341
 - vs placebo, 327
- Astemizole, 196t
- Asymptomatic AF, 63
- Atenolol, 254, 256t, 262
- ATHENA trial, 192, 224-228, 226-227, 228
- Atherosclerotic plaque, 279
- Athletes, 49, 50
- Atorvastatin, 92-93, 94t-95t, 96
- Atria
 - anatomy of, 167
 - electrophysiologic properties of, 153-158, 158
- ATRIA study, 23
- Atrial defibrillators, 147-148
- Atrial dilatation, 46t, 50, 51
- Atrial-esophageal fistula, 170, 172t
- Atrial fibrillation (AF)
 - classification of, 17-21, 20
 - consequences and prognosis of, 27-31

Atrial fibrillation (AF) (*continued*)

- definition of, 13
- mechanism of, 33-39
- perpetuation of ("AF begets AF"), 37-38, 83-86
- therapeutic approaches, 110-111. See also *Therapy*.
 - variety of clinical presentations in, 63, 66
- Atrial Fibrillation Investigators (AFI), 289
- Atrial fibrosis. See *Fibrosis*.
- Atrial flutter, 16-17, 17, 18, 56
 - after catheter ablation, 172
 - anticoagulation for, 335-338
 - conversion of AF to, 150, 195-196
- Atrial natriuretic peptide (ANP), 42, 58
- Atrial proarrhythmias, 195-196
- Atrial remodeling, 46t, 50, 51, 83-86, 149, 164
 - prevention of, 86, 87, 88t
 - regression with AADs, 191
- Atrial selective AADs, 153-162, 161, 163t
- Atrial septal defect (ASD), 52
- Atrial size/volume, 35, 37, 58, 73
- Atrial stretch, 38
- Atrial tachycardia, 16, 17. See also *Tachycardia*.
- Atrial torsade, 196
- Autoimmune processes in AF, 37
- Autonomic nervous system/tone, 39, 46t, 202
- AV junction RV ablation, 116t-117t
- AV nodal ablation, 267-269, 275-276
 - risks and complications of, 268-269
- AV nodal agents, 250, 253-261. See also *Rate control*.
 - combination therapy with, 271, 273-275, 274, 276
- AV nodal block, 196, 204t, 273
- AV nodal modification, 269
- AV nodal vagal stimulation, 269
- AVERRROES trial, 324-325
- Azathioprine, 312t

- BAATAF, 298-300
- BAFTA study, 302-303
- Barbiturates, 313t
- β -Agonists, 53
- β -Blockers, 87, 254-256, 255t-256t
 - clinical studies, 116t-117t
 - combination therapy, 273-275, 274, 276
 - with statins, 93-96
 - contraindications/cautions, 256
 - drug interactions, 217, 243
 - indications for, 54, 150, 203, 208, 254-256
 - for rate control, 254-256
 - acute control, 270-271, 274-275
 - chronic control, 273-275, 276
- Birmingham schema of stroke risk, 291-293, 293t
- Blood pressure, 59
 - hypertension, 49-50, 59. See also *Hypertension*.
 - hypotension, 63, 152, 156t, 257
- Blood stasis, thromboembolism and, 280
- Blood tests, 70t, 74-75
- Blue toe syndrome, 315
- BNP. See *Brain natriuretic peptide*.
- Body mass index (BMI), 53, 59

Bosentan, 312t
 Bradyarrhythmia, 196-197
 Bradycardia, 140, 150, 156t, 195, 196-197, 204t
 CCB cautions in, 257
 rate-control therapy and, 252-253
 Brain imaging, 283, 335
 Brain natriuretic peptide (BNP), 42, 58, 77
 Bypass surgery. See *CABG*.

 C-reactive protein (CRP), 35-37, 58, 93, 281
 CABANA trial, 175-179
 CABG, post-surgery AF and, 46t, 53, 55-56, 57, 57
 anticoagulation, 338-339
 case study, 357-359
 steroid therapy and, 97-99, 98
 CAFA, 298-300
 Caffeine, 26, 55
 Calcium channel blockers (CCBs), 87, 256-257, 258t
 combination therapy, 271, 273-275, 274, 276
 drug interactions, 243
 for rate control, 256-257, 258t, 271
 acute control, 270-272
 chronic control, 273-275, 276
 for repeat cardioversion, 144
 Calcium loading, 38, 87
 Canadian Cardiovascular Society Severity in Atrial Fibrillation (CCS-SAF)
 scoring system, 71, 72t
 Canadian trials. See *CTAF*; *CTOPP*.
 Candesartan, 88-89
 CAPP, 89
 Captopril, 89
 CARAF I and II studies, 96, 242
 Carbamazepine, 313t
 Cardiac conditions associated with AF, 49-52, 59
 Cardiac pacemakers. See *Pacemakers*.
 Cardiac surgery, post-operative AF and, 51, 55-56, 57, 57
 anticoagulation for, 338-339
 steroid therapy and, 97-99, 98
 Cardiac tamponade, 171, 172t
 Cardioembolic stroke, 281-284, 327
 Cardiomyopathy, tachycardia-induced, 40, 41, 63
 Cardiovascular disease
 AF and, 25
 exercise and, 83
 Cardiovascular drugs, 312t
 Cardiovascular Health Study (CHS), 23, 83, 84t-85t
 Cardioversion, 132-162. See also *Electrical cardioversion*; *Pharmacologic cardioversion*.
 anticoagulation for, 132, 149-150, 328-334, 336-337
 prevention of new thrombus, 333-334, 333
 risk of preexisting thrombus, 330-333
 atrial defibrillators, 147-148
 electrical, 131, 132-148
 internal, 147
 pharmacologic, 148-162
 spontaneous, 148
 TEE-guided, 330-333
 CARTO, 168-169

 Carvedilol, 256t
 drug interactions, 156t, 240
 Case studies, 353-363
 AF patient with stent placement, 361-363
 AF post-CABG, 357-359
 AF with hyperthyroidism, 359-361
 elderly patient with new-onset AF, 355-357
 lone AF, 353-355
 CAST, 76, 113, 208-209, 241-242
 Catecholamines, 33
 Catheter ablation, 162-180
 clinical trials, 174-179, 176t-178t, 179
 complications, 170-171, 172t, 174
 ESC Guidelines, 180, 182-183
 focal triggers, 163-164, 164
 follow-up and recurrence of AF, 171-173
 indications for, 179-180, 182-183, 207
 outcomes and further management, 173-174
 periprocedural management, 168-169
 anticoagulation, 169
 imaging, 168-169
 safety and efficacy, 174-179, 176t-178t, 179
 techniques, 165-168, 167
 circumferential left atrial vein ablation, 167, 168
 cryoablation balloon catheter, 175
 ostial pulmonary vein isolation, 165-167, 167
 other techniques, 168
 vs antiarrhythmic therapy (AADs), 174-179, 176t-178t, 179
 CCBs. See *Calcium channel blockers*.
 Cephalosporins, 312t
 Cerebral thromboembolism, 282-284
 Cerebrovascular accident (CVA), 63, 170-171
 CHADS2 score, 60, 289-291, 289t
 CHADS2DS2-VASc, 293-294, 293t
 CHARM trial, 88-89
 Chest imaging, 69, 71t, 75, 201t
 Chest pain, 42, 64-65
 Chloroquine, 196t
 Cholesterol embolization, 315
 Cholestyramine, 312t
 Chronic inflammatory conditions, 26
 Chronic medical conditions, 25, 46t, 60, 63
 Chronic obstructive pulmonary disease (COPD), 52-53
 Chronotropic incompetence, 253
 Cigarette smoking, 55
 Cimetidine, 236, 313t
 Ciprofloxacin, 311
 Cisapride, 196t
 Clarithromycin, 311, 323
 Classification of AF, 17-21, 20, 66
 episodes shorter than 30 seconds, 19-20
 first-detected episode, 19, 20
 lone AF, 20-21
 long-standing persistent AF, 19
 paroxysmal AF, 19, 20
 vs persistent, 166
 permanent AF, 19, 20
 persistent AF, 19, 20, 166

Classification of AF (*continued*)

- recurrent episode, 19
- secondary to other conditions, 20
- Classification of symptoms, 72t
- Clinical manifestations, 63-68
 - asymptomatic AF, 63
 - differential diagnosis of chest pain, 64-65
 - poor correlation with presence of AF, 66, 67, 76
 - subclinical manifestations, 82
 - variations in, 63, 66
- Clinical trials and studies
 - ACT I-IV trials, 160-161
 - ACTIVE-A, 328
 - ACTIVE-W, 303-304, 328
 - ACUTE, 331-332
 - ACUTE II, 332
 - ADONIS, 222-223, 229
 - AF-CHF, 120, 124-125
 - AF Symptoms Study, 269
 - AFASAK, 298-300, 302
 - AFFIRM, 31, 114-122, 116t-117t, 119, 124, 126, 192, 212, 217-218, 250-251, 261, 267
 - AFI, 289
 - Aggrastat to Zocor (A to Z) Trial, 93
 - ANDROMEDA, 223-224
 - ARISTOTLE, 325
 - ARMYDA3, 92, 93, 96
 - ATHENA, 192, 224-228, 226-227, 228
 - ATRIA, 23, 24
 - AVERROES, 324-325
 - BAATAF, 298-300
 - BAFTA, 302-303
 - CABANA trial, 175-179
 - CAFA, 298-300
 - CAPP, 89
 - CARAF I and II studies, 96, 242
 - Cardiovascular Health Study (CHS), 23, 83, 84t-85t
 - CAST, 76, 113, 208-209, 241-242
 - CHARM, 88-89
 - Copenhagen Stroke Study, 28
 - COPPA II, 242
 - CRAFT, 160
 - CRRRAFT, 125
 - CTAF, 120-121, 218, 218, 232-233, 241
 - CTOPP, 101
 - Danish Diet, Cancer, and Health Study, 55, 100
 - DIAMOND, 28-29, 120, 209, 237
 - Digitalis Investigation Group (DIG) study, 29
 - DIONYSOS, 228-229
 - EAFI, 300-301
 - EMERALD, 236-237
 - EPOCH, 50
 - ERAFT, 241
 - ERATO, 223, 263
 - EURIDIS, 222-223, 229
 - EuroHeart Failure Survey, 29
 - Framingham Study, 23, 26, 28, 29, 47, 50, 54-55, 294
 - GISSI-AF trial, 91
 - HOT CAFE, 114, 116t-117t, 120, 121

Clinical trials and studies (*continued*)

- J-RHYTHM, 123-124
- LIFE, 89
- Manitoba study, 29, 49-50
- MIWAF, 302
- MOST, 101
- Niigata Preventive Medicine Study, 53-54
- ONTARGET, 90
- PAF-2, 123
- PATAF, 302
- PAVE, 267, 268
- PIAF, 114, 116t-117t, 120, 121
- PROTECT-AF, 345-347
- PROVE IT-TIMI 22, 93
- RACE, 114, 116t-117t, 119, 120, 212, 250
- RACE II, 251-252
- RAFT, 241
- RE-LY, 318-322, 319, 320t
- Rochester Epidemiologic Project, 23, 26
- ROCKET-AF, 323-324
- Rotterdam Study, 23, 28, 55
- SAFE-T, 120-121, 121, 217, 231-232, 232
- SAFIRE-D, 236
- SAVEPace, 101
- SOLVD, 28, 87-88
- SPAF I, 74, 298-300, 327
- SPAF III, 289, 301-302
- SPINAF, 283, 298-300
- STAF, 114, 116t-117t, 120
- STOP-2, 89
- TRACE, 87
- TRANSCEND, 90
- Valsartan Heart Failure Trial (Val-HeFT), 89
- VALUE, 89
- Veterans Affairs Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy, 219
- WOEST, 341
- Women's Health Initiative Study, 100
- Women's Health Study, 55, 99
- Clonidine, 264-265, 275, 276
- Clopidogrel, 299, 303-304
 - bleeding risk, decreasing, 340-341
 - in combination with aspirin, 297, 328
 - drug interactions, 310, 312t
- CNS agents, 313t
- Coffee consumption, 26, 55
- Computed tomography. See *CT scans*.
- Conduction block, 34, 35, 168
- Congenital heart disease, 52
- Connexins, 38
- Consequences of AF, 27-31
 - hospitalizations and costs, 29-31, 30
 - impaired hemodynamics, 28-29
 - mortality, 29
 - quality of life, reduced, 31
 - thromboembolism, 27-28
- Copenhagen Stroke Study, 28
- COPPA II, 242
- Coronary artery bypass graft. See *CABG*.

Coronary artery disease (CAD), 51, 64, 66
 AADs for, 207, 208-209
 Coronary interventions, anticoagulation for, 339-341
 Corticosteroids, 88t, 96-99, 98, 102
 Costs of AF, 29-31, 30
 Cox, James, 181
 Cox-Maze procedure, 180-187, 184. See also *Surgical ablation*.
 COX-2 inhibitors, 310-311, 312t
 CRAFT, 160
 Creatinine clearance, 317-318
 Creatinine, serum, 216, 235
 CRRAFT, 125
 Cryoablation, 185, 186
 CT scans, 75, 169, 283, 335
 CTAF, 120-121, 218, 218, 232-233, 241
 CTOPP, 101
 CYP1A2 system, 305
 CYP2C9 system, 305, 306, 309-310
 CYP2D6 system, 159, 238
 CYP3A4 system, 221, 236, 305, 323, 324

Dabigatran etexilate, 111, 299, 316-322, 356, 363
 dosing, 317
 drug interactions, 317
 FDA approval in AF, 322
 interruption/switching of therapy, 317-318
 RE-LY trial, 318-322, 319, 320t

Danish Diet, Cancer, and Health Study, 55, 100

Decompensated heart failure, 63, 204t, 256, 272

Defibrillation, atrial, 110, 147-148

Definition of AF, 13

Dementia, 28

Demographics of AF, 26-27

Device-based therapy, 101-102. See also *Pacemakers*.

Dexamethasone, 97

Diabetes, 21

Diagnosis of AF. See also *Classification of AF: Evaluation of patient with AF*.
 clinical manifestations, 63-68, 64-65
 differential, 16, 64-65
 electrocardiogram (ECG) in, 13-16, 15
 dilemma of, 14-16
 pacemakers and, 16
 patient evaluation, 69-80
 testing, 70t-71t

DIAMOND study, 28-29, 120, 209, 237

Diaphragmatic paralysis, 171

Dicloxacillin, 312t

Diet, low-salt, 81-83

DIG study, 29

Digitalis, 29, 116t-117t, 203

Digoxin, 257-261, 260t
 clinical studies, 115
 combination therapy, 274, 275, 276
 contraindications/cautions, 152, 196, 260
 dosing, 259, 260t
 drug interactions, 156t, 157t, 240, 257, 260, 263, 264
 indications for, 257-259, 272, 273, 274
 for rate control, 257-261, 260t, 262, 271, 276

Diltiazem, 256-257, 258t, 262, 271
 clinical studies, 116t-117t, 222
 contraindications/cautions, 203, 256-257
 drug interactions, 257

DIONYSOS study, 228-229

Direct thrombin inhibitors, 316-322

Disopyramide, 204t, 242-244
 clinical studies, 116t-117t, 244
 drug interactions, 243
 hemodynamic effects, 198
 implanted device threshold effects, 197t
 monitoring, 200t-201t

Disulfiram, 313t

Dobutamine, 55

Dofetilide, 155t, 205t, 233-238
 action mechanism, 205t, 233
 adverse effects, 150, 155t, 205t, 234
 clinical studies, 236-238
 DIAMOND, 28-29, 120, 209, 237
 contraindications/cautions, 234
 dosing, 205t, 234
 drug interactions, 234-236
 implanted device threshold effects, 197t
 indications for, 152t, 155t, 203, 207, 208, 209
 maintenance of NSR, 233-238
 initiation of therapy, 209-210, 211t, 235
 monitoring, 199, 200t-201t
 pharmacokinetics, 233
 safety of, 198

Domperidone, 196t

Doppler imaging, 58

Dronedarone, 205t, 219-229
 action mechanism, 205t
 adverse effects, 196, 205t, 221
 clinical studies, 222-229
 ATHENA, 192, 224-228, 226-227, 228
 contraindications/cautions, 198, 209, 221
 dosing, 205t, 220-221
 drug interactions, 221-222, 260, 263
 implanted device threshold effects, 197t
 indications for, 203, 207, 208
 ESC recommendations, 182-183
 maintenance of NSR, 219-229
 for rate control, 263, 275, 276
 initiation of therapy, 211t
 monitoring, 199, 200t-201t
 pharmacokinetics, 219-220
 safety of, 195, 198, 263

Droperidol, 196t

Dyspepsia, 317, 321

Dyspnea, 66, 253

EAFT trial, 300-301

Echocardiography, 73-74, 201t, 202
 stroke risk assessment with, 296-297, 297t
 transesophageal (TEE), 69, 70t-71t, 296-297, 297t
 transthoracic (TTE), 69, 73-74, 77, 296, 297t

EHRA scoring system, 71, 72t

- Elderly patients. See also *Age*.
 amiodarone cautions in, 208
 case study, 355-357
 degeneration of conduction system in, 140, 266, 273
 hospitalizations in, 29, 30
 lifetime risk and, 26
 neurologic evaluation, 76
 prevalence/incidence of AF in, 23-24, 24
 rate-control strategy in, 127, 127t, 271t, 273
 verapamil cautions in, 257
- Electrical cardioversion, 132-148
 checklist prior to, 133t
 complications of, 140-141
 indications for, 132-133, 149
 outcomes and further management, 141-147, 142
 approaches to increase success, 145t
 failed cardioversion, 144-145
 pharmacologic facilitation of, 146-147, 146t, 147t
 recurrence of AF, 142-144, 142
 repeat cardioversion, 143-144, 145
 AADs facilitating, 143-144, 143t, 144t
 restoration of NSR, 141-142
 practical and technical aspects, 133-140
 anesthesia, 133-134
 anticoagulation, 134-135
 energy delivered, 137-139
 pads/paddle use, 135, 136
 shock synchronization, 137
 shock waveforms, 137, 138
 special populations, 139-140
 acute MI, 139
 hyperthyroidism, 140
 implanted device, 139
 post-cardiac surgery, 139
 pregnancy, 140
 stroke risk and, 134, 141
- Electrical currents, 153-159, 158
- Electroanatomic mapping, 168-169
- Electrocardiogram (ECG), 13-16, 15, 70t, 73, 202
 in AAD monitoring, 199-202, 200t
 ambulatory recordings/monitoring, 75, 77-78, 79t, 273
 of atrial flutter, 18
 continuous recording, 200t, 202
 δ wave on, 76
 risk assessment with, 58
- Electrolyte testing, 199, 200t, 202
- Electrophysiologic properties of atria, 153-158, 158
- Electrophysiology study (E PS), 69, 71t, 76, 77
- Embolism. See *Thromboembolism*.
- EMERALD trial, 236-237
- Enalapril, 87-88
- Encainide, 209
- Endothelial and endocardial abnormalities, 279
- Endoxaban, 322
- Endurance sports exercise, 49, 50, 83
- Epidemiology of AF, 23-32
 consequences and prognosis of AF, 27-31
 demographics, 26-27
 lifetime risk, 26
- Epidemiology of AF (*continued*)
 prevalence and incidence, 23-26, 24, 25
 risk factors for AF, 25-26
- EPOCH study, 50
- ERAFT, 241
- ERATO study, 223, 263
- Erythromycin, 323
- ESC Guidelines. See *ACC/AHA/ESC Guidelines*.
- Esmolol, 255t, 271
- Ethnicity. See *Race/ethnicity*.
- Etiology of AF, 45, 46t, 60. See also *Risk factors*.
- Etomidate, 134
- EURIDIS, 222-223, 229
- EuroHeart Failure Survey, 29
- European Heart Rhythm Association (EHRA) scoring system, 71, 72t
- European Society of Cardiology. See *ACC/AHA/ESC Guidelines*.
- Evaluation of patient with AF, 69-80, 70t-71t
 follow-up encounters, 76-78
 minimum evaluation, 70t
 monitoring strategies, 76-78, 79t
 new-onset evaluation, 69-76, 70t-71t, 78
 blood tests, 74-75
 chest imaging, 75
 echocardiogram, 73-74
 electrocardiogram, 73, 78
 electrophysiology study, 69, 71t, 76
 exercise stress testing, 75-76, 273
 history, 69-72
 physical examination, 72-73
 symptom scoring systems, 71, 72t
- Event monitoring, 69, 71t
- Exercise, 81-83, 84t-85t, 102
 AF risk and, 49, 50, 83
 capacity/tolerance, 121, 121t, 253
 heart rate goals in, 250-253, 254t
 testing, 70t, 75-76, 201t, 202, 273
 warfarin use and, 315
- Extracellular matrix (ECM), 37-38, 83-86, 279, 281
- F (fibrillatory) waves, 14, 164
- Factor Xa inhibitors, 297, 299, 322-325
- Family history of AF, 45, 71
- Fatigue, 64, 66, 67, 253
- N*-3 fatty acids, 100
- Fentanyl, 134
- Fibrates, 312t
- Fibrosis, 35, 47, 86, 164, 169
- First-detected episode, 19, 20, 66
- Fish oil, 87, 100, 110, 312t
- Fistula, atrial-esophageal, 170
- Flecainide, 156t, 204t, 238-242
 action mechanism, 204t, 238
 adverse effects, 195-196, 198, 204t, 208-209, 239-240
 clinical studies, 116t-117t, 240-242
 contraindications/cautions, 240
 dosing, 204t, 239
 drug interactions, 240
 implanted device threshold effects, 197t

- Flecainide (*continued*)
- indications for, 203, 207
 - ESC recommendations, 182-183
 - maintenance of NSR, 238-242
 - pharmacologic cardioversion, 152, 152t, 156t
 - repeat electrical cardioversion, 143, 143t, 146
 - initiation of therapy, 210, 211t
 - monitoring, 199, 200t-201t
 - outpatient use of, 150, 151
 - pharmacokinetics, 238
- Flecainide/propafenone, 116t-117t
- Fluconazole, 312t
- Fluorouracil, 313t
- Fluvastatin, 312t, 313t
- Follow-up evaluation, 76-78
- Framingham risk score, 293, 294, 295
- Framingham Study, 23, 26, 28, 29, 47, 50, 54-55, 294
- Gender factors, 24, 24, 27
 - thromboembolic risk, 291, 292t
- Genetic AF, 45, 47-49, 60, 71
- Genetics, in future AF prevention, 83
- GI agents, 236, 313t
- GISSI-AF trial, 91
- Glucocorticosteroids, 88t, 96-99, 98, 102
- Goals of therapy, 107-112, 108
- Griseofulvin, 312t
- Haloperidol, 196t, 313t
- Heart disease
 - AF and, 27, 45, 51-52, 63, 166
 - catheter ablation vs AADs in, 182-183
 - valvular, 51, 125, 185, 280, 288
- Heart failure (HF), 28-29, 50-51, 59
 - AAD therapy and, 192, 198, 207, 209
 - acute decompensated, 63
 - AF with, 124-125
 - β -blockers for, 254, 259
 - digoxin for, 259
 - decompensated, 63, 204t, 256
 - acute rate control in, 272
- Heart rate, 14, 16, 40, 76-77. See also *Rate vs rhythm control*.
- chronotropic incompetence, 253
 - with rate-control therapy
 - lower limit, 252-253, 254t
 - target (goal), 115, 250-253, 254t
 - upper limit, 250, 254t
- Hematocrit, elevated, 280
- Hemodynamic effects of AF, 28-29, 39-43
 - impaired coronary blood flow, 42
 - irregular ventricular rate, 40
 - loss of atrial contraction, 42
 - neurohormonal activation, 42-43
 - rapid heart rate, 40
- Hemodynamic stability, achieving, 108, 110-111
- Hemodynamically stable patients, rate control for, 249-279
- Hemodynamically unstable patients, rhythm control for, 131-132, 135, 139, 274, 336-337
- Heparins, 111, 335, 338, 340
 - cardioversion and, 135, 330-333, 336-337
 - catheter ablation and, 169
- Herbal supplements, 311, 314t
- Hispanics, 83
- History, 69-72, 70t, 198-199
 - family history, 45, 71
 - medication history, 72
 - social history, 71-72
- HIV protease inhibitors, 196t, 221
- HMG-CoA Reductase Inhibitors (statins), 87, 88t, 91-96, 102
- Holter monitoring, 69, 71t
- Hospitalizations for AF, 29-31, 30
- HOT CAFE, 114, 116t-117t, 120, 121
- HRS/EHRA/ECAS 2007 Expert Consensus Statement on Catheter and Surgical Ablation, 180
- Hydrocortisone, 97-98, 98
- Hypercoagulable state, 280-281
- Hypertension, 49-50, 59, 208, 334
 - ACE inhibitors and, 212
 - clonidine in, 275, 276
- Hyperthyroidism, 54, 140, 338
 - case study, 359-361
- Hypertrophic cardiomyopathy (HCM), 52, 63, 66
- Hypotension, 63, 152, 156t, 257
- Hypothyroidism, 215
- Ibutilide, 154t, 272, 274
 - implanted device threshold effects, 197t
 - indications for, 154t, 272, 274
 - failed electrical cardioversion, 146-148, 146t, 147t
 - pharmacologic cardioversion, 152, 152t, 154t
 - repeat electrical cardioversion, 143, 143t
 - safety of, 146, 150
- Idiopathic AF, 45-47, 46t
- Imaging, 168-169
- Implanted devices, 265-269. See also *Pacemakers*.
 - electrical cardioversion and, 139
 - monitoring, 201t
 - threshold effects of AADs, 197, 197t, 217
- Incidence of AF, 23, 24
- Individualized approach to therapy, 107-109, 108, 127t
- Inflammation, 26, 35-37, 39, 46t, 93
 - AF prevention and, 87
 - anti-inflammatory agents, 86, 91, 310-311, 312t
 - conflicting data on, 96
 - thromboembolic risk and, 281
- Initiating event, 33-36, 34, 36
- Inpatient settings (AADs), 150-151, 209-211, 211t
- INR level, 306-307, 308-309, 309
- Interferon, 312t
- Internal cardioversion, 147
- Irbesartan, 303-304
- Isoniazid, 312t
- Isoproterenol, 39
- Japanese Rhythm Management Trial for Atrial Fibrillation (J-RHYTHM), 123-124

- Ketoconazole, 196t, 236, 317, 323
- Labetalol, 254
- Laboratory data, 58
- Lactation, 315
- Laser ablation, 185, 186
- Left atrial appendage (LAA), 342-348
 - closure devices, 342-347, 343, 344
 - surgical amputation/ligation, 347-348
- Left atrial thrombus, 74
- Left atrial vein ablation, 167, 168
- Left atrium. See also *Atria*.
 - reservoir function, 37, 58
 - size/volume, 35, 37, 58, 73
- Left ventricular dysfunction, 28, 40, 63
- Left ventricular end diastolic pressure (LVEDP), 42
- Left ventricular hypertrophy (LVH), 50, 208
- LIFE trial, 89
- Lifestyle modifications, 81-83
- Limb ischemia, 286t
- Liver function tests, 75, 77, 199
- LMWH, 330, 332-333, 336-337, 338, 340. See also *Heparins*.
- Lone AF, 20-21, 45-47
 - case study, 353-355
- Long-standing persistent AF, 19
- Loop diuretics, 196t
- Losartan, 89
- Lovastatin, 312t
- Macrolides, 196t, 221, 312t
- Magnesium level assessment, 199, 200t
- Magnesium sulfate, 265
- Manitoba study, 29, 49-50
- Mechanism of AF, 33-39, 34
 - “AF begets AF,” 37-38, 83-86
 - arrhythmia substrate, 35-37
 - focal activation vs multiple wavelets, 36
 - initiating event, 33-36, 34, 36
 - modulating factors, 38-39
 - multiple-source hypothesis, 34, 35, 36
 - single-focus theory, 33-35, 34, 36
- Medical conditions, chronic/associated, 25, 46t, 60, 63, 338-339
- Medication history, 72
- Medications, AF and, 55
- Mefloquine, 196t
- Megestrol, 236
- Mesalamine, 312t
- Mesenteric ischemia, 286t
- Metabolic syndrome, 53-54
- Metalloproteinase activity, 38
- Methadone, 196t
- Methylprednisolone, 96-97
- Metoprolol, 255t
 - drug interactions, 156t, 240
- Metronidazole, 311, 312t
- Midazolam, 134
- Milrinone, 55
- Mitral stenosis, 280, 292t
- MIWAF, 302
- Mode Selection Trial (MOST), 101
- Monitoring, 76-78, 79t
 - AADs, 198-202, 200t-201t
- Mortality, 29, 115-118, 118
 - catheter ablation and, 171, 172t
- MOST, 101
- MRI, 169, 283
- Multifocal atrial tachycardia (MAT), 53
- Multiple-source hypothesis, 34, 35, 36
- Myocardial infarction (MI)
 - acute, 51, 64
 - AF during hospitalizations for, 56
 - DC cardioversion and, 139
 - transient AF during, 56
 - AF secondary to, 20, 46t
 - anticoagulation for AF in, 338
 - precipitated by AF, 66
- N*-acetylcysteine (NAC), 100
- n*-3 Polyunsaturated fatty acids (PUFAs), 100
- NAC (*N*-acetylcysteine), 100
- Nadolol, 254
- Nafcilin, 312t
- National Heart, Lung, and Blood Institute, 81
- NavX, 168-169
- Neurohormonal activation, 42-43, 91
- Neurologic evaluation, 76
- Nexterone, 214
- NICE guidelines, 291
- Niigata Preventive Medicine Study, 53-54
- Nitric oxide, 91
- Nondihydropyridine CCBs. See *Calcium channel blockers*.
- Nonpharmacologic therapy. See also *Implanted devices; Surgical ablation*.
 - for AF prevention, 81-83
 - for rate control, 265-270, 266t
 - for stroke prevention, 341-347
- Norepinephrine, 43
- Normal sinus rhythm (NSR)
 - desirability as goal, 113, 120-121, 122, 126, 127
 - maintenance of, AADs for, 191-248
 - restoration of, 131-190
 - catheter ablation, 162-180
 - electrical cardioversion, 132-148
 - pharmacologic cardioversion, 148-162
 - surgical options, 180-187
- NSAIDs, 310, 312t, 341
- Obesity, 53
- Obstructive sleep apnea, 53
- Ocular effects, 216
- Omeprazole, 313t, 341
- ONTARGET trial, 90
- Oral contraceptives, 313t
- Organ toxicity, 198
- Outpatient settings (for AADs), 150-151, 209-211, 211t
- Oxidation, 87, 91, 99-100

- P waves, 13, 58
- Pacemakers, 265-269, 275-276
 - ACC/AHA/HRS device guidelines, 101
 - AF diagnosis and, 16
 - AF prevention and, 101-102
 - choice of, 267
 - bi-ventricular, 267
 - dual-chamber, 267
 - single-chamber, 267
 - electrophysiology testing prior to, 77
- PAF/PAF-2 trials, 100, 123
- Parasympathetic nervous system, 39, 250, 264
- Paroxysmal AF, 19, 20, 33-34, 39, 338-339
 - clinical trials, 100, 123
 - rate vs rhythm control in, 123-124
 - vs persistent AF, 166
- PATAF, 302
- Pathophysiology of AF, 33-44, 34. See also *Risk factors*.
 - hemodynamic effects, 39-43
 - impaired coronary blood flow, 42
 - irregular ventricular rate, 40
 - loss of atrial contraction, 42
 - neurohormonal activation, 42-43
 - rapid heart rate, 40
 - mechanism of AF, 33-39
 - "AF begets AF," 37-38, 83-86
 - arrhythmia substrate, 35-37
 - inflammation and, 39
 - initiating event, 33-36, 34, 36
 - modulating factors, 38-39
 - in older adults, 83
 - thromboembolism and, 279-281
- Patient evaluation. See *Evaluation of patient with AF*.
- Patterns of AF, 17-21, 20
- PAVE study, 267, 268
- PCI, anticoagulation and, 339-341
- Pentamidine, 196t
- Percutaneous closure of LAA, 342-347, 343, 344
- Pericarditis, 51-52, 65
- Permanent AF, 19, 20
- Persistent AF, 19, 20, 165
 - vs paroxysmal AF, 166
- Pharmacologic cardioversion, 148-162
 - ACC/AHA/ESC Guidelines, 151, 152, 152t, 180, 182-183
 - choice of AADs for, 152-153, 154t-157t
 - duration of AF and, 152t
 - factors to consider, 153t
 - new (atrial selective) AADs, 153-162, 161, 163t
 - contraindications/cautions, 150, 152
 - efficacy of, 148-149
 - indications for, 149
 - safety of, 149-151
 - anticoagulation, 149-150
 - inpatient vs outpatient settings, 150-151
 - toxicity of AADs, 150
 - timing of, 148, 149
- Pharmacologic prevention of AF, 83-100. See also *Prevention of AF*.
- Phenothiazines, 196t
- Phenytoin, 313t
- Photosensitivity, 216
- Physical examination, 72-73
- Physical exercise, 81-83, 102
- PIAF trial, 114, 116t-117t, 120, 121
- Pill-in-the-pocket strategy, 150, 151, 210
- PLAATO, 342, 343
- Platelet activation, 280-281
- Pleuritis, 65
- Pneumonia, 65
- N-3 Polyunsaturated fatty acids (PUFA), 100
- Postoperative AF, 46t, 55-56, 57, 57, 192
 - anticoagulation for, 338-339
 - case study, 357-359
 - fish oil and, 100
 - steroid therapy and, 97-99, 98
- Potassium channels, 47
 - blockade of, 205t
- Potassium level assessment, 199, 200t
- PR interval, 58, 59
- Prasugrel, 341
- Pravastatin, 93, 94t-95t
- Pregnancy
 - DC cardioversion in, 140
 - digoxin use in, 260-261
 - warfarin use in, 315
- Prevalence of AF, 23-26, 25
- Prevention of AF, 81-105, 110
 - device-based therapy in, 101-102
 - goals of, 81, 82
 - nonpharmacologic, 81-83
 - pharmacologic, 83-100, 87, 88t
 - AADs and, 211-212
 - ACE inhibitors/ARBs, 86-91
 - aldosterone antagonists, 86, 91
 - antioxidants, 99-100
 - fish oil, 100
 - glucocorticosteroids, 96-99, 98
 - RAAS blockade, 86-91
 - statins, 91-96
 - recurrence prevention, 191
- Prevention of thromboembolism in AF, 279-352. See also *Thromboembolism*.
- Proarrhythmias, 150, 158, 193-197, 204t
 - atrial, 195-196
 - ventricular, 193-195, 194
- Procainamide, 146, 146t, 152, 272, 274
- Prochlorperazine, 236
- Prognosis of AF, 27-31
- Propafenone, 156t, 204t, 238-242
 - action mechanism, 204t, 238
 - adverse effects, 195-196, 197-198, 204t, 209, 239-240
 - clinical studies, 116t-117t, 240-242
 - contraindications/cautions, 156t, 208, 240
 - dosing, 204t, 239
 - drug interactions, 240, 260, 264, 312t
 - implanted devices and, 197t
 - indications for, 203, 207
 - ESC recommendations, 182-183
 - maintenance of NSR, 238-242
 - pharmacologic cardioversion, 150, 151, 152, 152t, 156t

- Propafenone, indications for (*continued*)
 for rate control, 264
 repeat electrical cardioversion, 143, 143t, 144, 144t, 146
 initiation of therapy, 210, 211t
 monitoring, 199, 200t-201t
 outpatient use of, 150, 151
 pharmacokinetics, 238
- Propofol, 134
- Propranolol, 257, 271
- Protease inhibitors, 196t, 221
- PROTECT-AF, 345-347
- Prothrombic state, 280-281
- Prothrombin time, 75, 305, 306-307
- Proton pump inhibitors, 341
- PROVE IT-TIMI 22, 93
- Psychosocial factors, 26
- Psychotropic drugs, 196t
- PUFAs, 100
- Pulmonary disease, 52
- Pulmonary embolus (PE), 52, 65, 284
- Pulmonary function tests, 199, 201t
- Pulmonary vascular and pulmonary disease, 52-53
- Pulmonary vein isolation, 37, 165-167, 167
- Pulmonary vein stenosis, 167, 170
- Pulmonary veins (PVs), in paroxysmal AF, 33-34
- Purple toe syndrome, 315
- QRS complex, 14, 73, 76, 137
 wide, 76
- QT intervals, 58, 73, 77, 152
 prolonged, 194, 195
 drugs associated with, 196t
- Quality of life (QoL), 27, 31, 40, 82, 107, 108, 117t, 120-123, 173
- Quinidine, 144t, 152, 198
 drug interactions, 260, 317
- Quinolones, 196t, 312t
- RAAS (renin-angiotensin-aldosterone system) blockade, 86-91, 87, 88t, 102
 combination with AADs, 211-212
- Race/ethnicity, 27, 48, 83
- RACE, 114, 116t-117t, 119, 120, 212, 250
- RACE II, 251-252
- Radiofrequency ablation, 185, 186, 186t, 267-269
- RAFT, 241
- Ramipril, 90
- Ranolazine, 196t
- Rate control, 249-278. See also *Heart rate*.
 algorithms based on clinical presentation, 270-276
 acute pharmacologic rate control, 270-273, 271t, 274-275
 cautions in, 271t
 chronic pharmacologic rate control, 273-276, 276
 special populations, acute rate control in, 272-273
 bradycardia and, 252-253
 clinical benefit of, 249, 268
 follow-up assessments, 249
 goals and definitions in, 249-253, 250t
 nonpharmacologic therapy for, 265-270, 266t
 AV nodal ablation with pacemaker implantation, 267-269
 AV nodal modification, 269
- Rate control, nonpharmacologic therapy for (*continued*)
 chronic atrioventricular nodal vagal stimulation, 269
 gene therapy, 270
 pacemaker implantation, 265-267
 regularization of ventricular response with pacing, 269
- pharmacologic agents for, 253-261
 acute control with, 270-272, 274-275
 antiarrhythmic drugs, 262-264, 275
 β -blockers, 254-256, 255t-256t
 cautions in titration of therapy, 271t
 CCBs, 256-257, 258t
 chronic control with, 273-276, 276
 combination therapy, 254, 259, 262, 271, 273-275, 274, 276
 comparative studies of, 261, 262. See also *AFFIRM trial*.
 digoxin, 257-261, 260t
 other agents, 264-265
 clonidine, 264-265
 magnesium sulfate, 265
 strict vs lenient control, 251-252
 vs rhythm control, 113-129, 116t-117t. See also *Rate vs rhythm control*.
- Rate vs rhythm control, 113-129
 age and, 122
 choice of strategy, 110, 126, 127t
 clinical trials: description, 114, 116t-117t
 clinical trials: outcomes, 114-122
 cost-effectiveness, 122
 CV mortality, 118, 118
 exercise tolerance, 121, 121
 heart failure, impact on, 120
 hospitalization, 122
 symptoms and QoL, 31, 117t, 120-121
 thromboembolic complications, 118-120, 119
 total mortality, 115-118, 118
 clinical trials: specific populations, 122-125
 AF and heart failure, 124-125
 symptomatic, paroxysmal AF, 123-124
 young patients with AF and valvular heart disease, 125
 goals of, 113
 normal sinus rhythm, 113, 120-121, 122, 126, 127
 patient characteristics and, 127t
 safety and efficacy of, 113-114
 stroke rates and, 191, 288
- RE-LY trial, 318-322, 319, 320t
- Reactive oxygen species, 87, 91
- Recurrence of AF, 19
 AADs in prevention of, 191, 192, 202
 catheter ablation and, 171-173
 electrical cardioversion and, 142-144, 142
 immediate recurrence (IRAF), 142, 142, 143-144
 late recurrence, 142, 142, 172
 subacute (early) recurrence (ERAF), 142, 142, 171
 very late recurrence, 173
- Registry of Information and Knowledge About Swedish Heart Intensive Care
 Admissions (RIKS-HIA), 259
- Remodeling. See *Atrial remodeling*.
- Renal function tests, 75, 77, 199, 200t
- Renal thromboembolism, 287t
- Renin-angiotensin-aldosterone system. See *RAAS*.
- Rheumatic heart disease (RHD), 51

Rhythm control, 131-190. See also *Normal sinus rhythm; specific topics*.
 antiarrhythmic drugs and, 191-248
 catheter ablation, 162-180
 electrical cardioversion, 132-148
 indications for, 131, 132-133, 192
 pharmacologic cardioversion, 148-162
 surgical options, 180-187
 vs rate control, 113-129, 116t-117t. See also *Rate vs rhythm control*.

Rifampicin, 323
 Rifampin, 312t, 317

Right ventricular (RV) pacing, 101

Risk assessment, 58-60, 59
 ancillary studies for, 58
 for stroke, 285-297

Risk factors, 45-62, 46t
 assessment with ancillary studies, 58
 cardiac/noncardiac conditions associated with AF, 46t, 49-56
 alcohol and other toxins, 54-55
 cardiac surgery, 55-56
 congenital heart disease, 52
 coronary artery disease and acute MI, 51
 heart failure, 50-51
 hypertension, 49-50
 hyperthyroidism, 54
 hypertrophic cardiomyopathy, 52
 medications, 55
 metabolic syndrome, 53-54
 obesity, 53
 pericarditis, 51-52
 pulmonary vascular and pulmonary disease, 52-53
 supraventricular arrhythmias, other, 56
 valvular heart disease, 51

idiopathic AF, physiologic, and genetic factors, 45-49
 aging, 47
 endurance sports exercise, 49, 50
 genetic AF, 47-49, 60
 lone AF, 45-47
 lifetime risk, 26
 prevalence of AF and, 25-26
 prevention and, 82
 reversible risk factors, controversies on, 56-57
 risk score assessment/algorithm, 58-60, 59

Risperidone, 196t

Ritonavir, 196t, 323

Rivaroxaban, 299, 322, 323-324

Rochester Epidemiologic Project, 23, 26

ROCKET-AF, 323-324

Rotterdam Study, 23, 28, 55

SAFE-T, 120-121, 121t, 217, 231-232, 232

SAFIRE-D, 236

SAVEPace trial, 101

Scar tissue, surgically created, 181, 184, 185

Scoring systems, 59, 71, 72t
 for thromboembolism risk, 285-297

Secondary AF, 20-21, 192

Sertraline, 313t

Shock therapy. See *Electrical cardioversion*.

Shock waveforms, 137, 138

Sick sinus syndrome, 273

Signaling pathways, 86

Simvastatin, 157t, 215, 222, 312t

Single-focus theory, 33-35, 34, 36

Sinoatrial (SA) nodal cells, 13

Sinus rhythm. See *Normal sinus rhythm (NSR)*.

Sirolimus, 222

Skin effects, 216

Sleep disorders, 53, 82

Smoking (tobacco), 55
 cessation of, 81-83

Social history, 71-72

Sodium channel blockade, 204t

SOLVD, 28, 87-88

Sotalol, 205t, 229-233
 action mechanism, 159, 205t, 229-230
 adverse effects, 195, 196, 205t, 230-231, 263
 clinical studies, 116t-117t, 231-233, 232
 SAFE-T, 120-121, 121t, 217, 231-232, 232
 contraindications/cautions, 152, 198, 231
 dosing, 205t, 230
 drug interactions, 231
 implanted device threshold effects, 197t
 indications for, 203, 207, 208
 ESC recommendations, 182-183
 maintenance of NSR, 229-233
 for rate control, 263-264, 275, 276
 repeat electrical cardioversion, 143, 143t, 146
 initiation of therapy, 209-211, 211t
 monitoring, 199, 200t-201t
 pharmacokinetics, 230
 underlying heart disease and, 182-183

SPAF I trial, 74, 298-300, 327

SPAF III trial, 289, 301-302

Special populations
 acute rate control in, 272-273
 electrical cardioversion in, 139-140
 thromboembolism prevention in, 328-341

SPINAF trial, 283, 298-300

Splenic infarction, 287t

Sports exercise, 49, 50, 83, 315

SSRIs, 196t, 313t

STAF trial, 114, 116t-117t, 120

Statins, 87, 88t, 91-96, 102, 110
 combined with β -blockers, 93-96
 drug interactions, 312t
 for stroke prevention, 299

Stents, 341, 361-363

Steroids. See *Glucocorticosteroids*.

STOP-2, 89

Stress (exercise) testing, 69, 70t, 75-76, 201t, 202, 273

Stroke. See also *Thromboembolism*.
 anticoagulation in patients presenting with, 334-335
 cardioembolic, 281, 281-284, 327
 diagnosis, 283
 ischemic, 282-284
 prevention in AF, 111, 279-352, 299. See also *Thromboembolism*.
 anticoagulation therapy and, 118-119, 119t, 298-315
 clinical studies. See *SPAF I; SPAF III*.

Stroke (*continued*)

- risk
 - AF and, 27-28, 282
 - catheter ablation and, 172t
 - stratification schemes in AF, 285-294, 289t, 292t, 293t, 295
 - surgical ablation and, 181, 185
 - warfarin reduction of, 118-119, 119
- silent, 283
- Studies of Left Ventricular Dysfunction (SOLVD), 28, 87-88
- Substrate for arrhythmia, 35-37
 - prevention strategies and, 82
- Sucralfate, 313t
- Supraventricular arrhythmias, other, 56
- Supraventricular tachycardia (SVT), 55
- Surgical ablation (Cox-Maze procedure), 180-187, 184
 - AF pattern, non-importance of, 181
 - AV nodal ablation with pacemaker implantation, 267-269, 275-276
 - benefits vs risks and complications, 181, 184t
 - Cox-Maze IV (bipolar radiofrequency), 185, 186, 267
 - benefits of, 186t
 - indications for, 181-185, 267
 - success rates, 180, 184t, 185
 - thromboembolic risk and, 181
 - variations on, 185
- Sympathetic nervous system/tone, 39, 71, 87, 250, 264
- Sympathomimetic drugs, 55
- Symptoms of AF, 13, 63-67, 64. See also *Clinical manifestations*.
 - hemodynamic, 39-43
 - lack of correlation with AF frequency/duration, 66, 67, 76
 - scoring/classification of, 71, 72t
- Syncope, 63-66, 64, 76
- Systolic blood pressure, 59

- Tachycardia
 - atrial, 16, 17, 53
 - supraventricular, 55
 - ventricular, 16, 193-195, 194
 - wide QRS complex, 76, 193-195, 194
- Tachycardia-induced cardiomyopathy, 40, 41, 63
- Tacrolimus, 222
- Tamoxifen, 313t
- Tamponade, 171, 172t
- TEE. See *Transesophageal echocardiography*.
- Telmisartan, 90
- Terfenadine, 196t
- Tetracycline, 312t
- Theophylline, 53, 55, 72
- Therapy. See also *Prevention of AF: specific topics*.
 - acute AF with uncontrolled ventricular response, 270-272, 274-275
 - antiarrhythmic drugs, 191-248
 - evidence-based approach to, 107
 - factors influencing, 109
 - goals of, 107-112, 108
 - long-term, 107, 108
 - primary, 107, 108
 - individualized approach to, 107-109, 108, 127t
 - nonpharmacologic
 - for AF prevention, 81-83
 - for rate control, 265-270, 266t

Therapy, nonpharmacologic (*continued*)

- for stroke prevention, 341-347
- rate vs rhythm control, 110, 113-129, 116t-117t
- rate control, 249-278
 - goals of, 249-253, 250t
 - nonpharmacologic therapy, 265-270, 266t
 - pharmacologic agents, 253-261
- rhythm control, 131-190
 - catheter ablation, 162-180
 - electrical cardioversion, 132-148
 - pharmacologic cardioversion, 148-162
 - surgical options, 180-187
- rhythm maintenance, antiarrhythmic drugs for, 191-248
- therapeutic approaches, 110-111
 - preventive therapy, 81-105, 110
 - stroke prevention, 111, 279-352
 - antiplatelet therapy, 325-328
 - nonpharmacologic methods, 341-347
 - oral anticoagulation, 298-325
 - pharmacologic agents, 297-298, 299
 - special situations, 328-341
 - surgical techniques, 347-348
- Thiazide diuretics, 196t, 234
- Thienopyridines, 339
- Thioridazine, 196t
- Thrombin inhibitors, direct, 297, 299
- Thromboembolism, 27-28, 279-352
 - catheter ablation and, 170-171
 - clinical presentation in AF, 281-284
 - diagnosis, 283
 - ischemic stroke and TIAs, 282-284
 - other complications, 284, 286t-287t
 - outcome and mortality, 284
- CVA, 63, 170-171
- diabetes and, 21
- pathophysiology in AF, 279-281
 - blood stasis, 280
 - endothelial and endocardial abnormalities, 279
 - hypercoagulable state, 280-281
- peripheral, 28, 284
- prevention in AF, 279-352
- preventive therapies, 111, 297-352, 299
 - anticoagulation therapy, 290-291, 292t, 297-315
 - AF ablation and Cox-Maze procedure, 334
 - AF patients presenting with stroke, 334-335
 - for cardioversion, 328-334
 - antiplatelet therapy, 325-328
 - LAA amputation or ligation, 347-348
 - LAA closure devices, 342-347, 343, 344
 - newer anticoagulants, 315-325
 - dabigatran etexilate, 316-322
 - factor Xa inhibitors, 322-325
 - nonpharmacologic methods, 341-347
- pharmacologic stroke prevention, 297-298, 299
- special situations, 328-341
 - AF ablation and Cox-Maze procedure, 334
 - AF due to reversible causes, 338-339
 - AF patients presenting with stroke, 334-335
 - atrial flutter, 335-338

Thromboembolism, preventive therapies, special situations (*continued*)

bleeding risk, decreasing, 340-341
cardioversion of AF, 328-334, 333
interruption of anticoagulation, 339, 340
patients with coronary interventions, 339-341
surgical techniques, 347-348
warfarin, 298-315
in rate- vs rhythm-control trials, 118-120, 119
risk stratification in AF, 285-297
 AF duration and, 329-330, 336-337
 Birmingham schema, 291-293, 293t
 CHADS2 score, 289-291, 289t
 CHADS2DS2-VASc, 293-294, 293t
 echocardiographic assessment, 296-297, 297t
 Framingham risk score, 293, 294, 295
 in new-onset AF, 294, 295
 TTE assessment for, 74
 surgical ablation and, 268-269
Thromboglobulin, 281
Thyroid conditions: hyperthyroidism, 54, 140, 338, 359-361
Thyroid hormones, testing, 54, 58, 74, 77, 199, 200t
TIA, 171, 335
Ticagrelor, 341
Toes, purple/blue toe syndrome, 315
Torsade de pointes (TdP), 146, 147, 150, 154t, 158
 AADs and, 193-195, 194, 204t-205t
TRACE study, 87
Trandolapril, 87
TRANSCEND study, 90
Transesophageal echocardiography (TEE), 69, 70t-71t
 prior to catheter ablation, 169
 stroke diagnosis with, 283
 stroke risk assessment with, 296-297, 297t
 TEE-guided cardioversion, 330-333
Transthoracic echocardiography (TTE), 69, 73-74, 77
 stroke risk assessment with, 296, 297t
Treatment of AF. See *Therapy*.
Trials and studies. See *Clinical trials and studies*.
Tricyclic antidepressants, 196t
Triggers of AF, 33-36, 34, 163-164, 164
 prevention strategies and, 82
Trimethoprim, 236
Trimethoprim-sulfamethoxazole, 311, 312t
Triple therapy, 339, 341
Troponins, cardiac, 141
TTE. See *Transthoracic echocardiography*.
UFH, 111, 332, 336-337, 338, 340. See also *Heparins*.
Vagal stimulation, 269
Vagal tone, 55, 71-72, 208
Val-HeFT, 89
Valsartan, 89
VALUE trial, 89
Valvular heart disease, 51, 125, 185
 thromboembolic risk and, 280, 288
Vaughan-Williams classification of AADs, 204t-205t
Ventricles, electrophysiologic properties of, 153-158, 158
Ventricular proarrhythmias, 193-195, 194

Ventricular rate, 14, 16, 40
 goals, with rate-control therapy, 250-253, 254t
 regularization with pacing, 269
Ventricular tachycardia, 16, 193-195, 194
Verapamil, 256-257, 258t
 AF recurrence and, 203
 clinical studies, 116t-117t
 contraindications/cautions, 256-257
 drug interactions, 155t, 222, 236, 257, 260, 317
 for rate control, 256-257, 258t
 for repeat cardioversion, 143, 143t, 144, 144t
Vernakalant, 159-162, 161, 163t, 354
 approval in EU, 161
 clinical trials, 160-161, 161
 side effects, 160, 163t
Veterans Affairs Congestive Heart Failure: Survival Trial of Antiarrhythmic Therapy, 219
Vitamin C, 87, 100
Vitamin E, 100
Vitamin K antagonists (warfarin), 297, 298-315, 299
Vitamin K-containing foods, 311-314, 314t
VKORC1 gene polymorphism, 306, 310
von Willebrand factor (vWF), 279, 280, 281
Voriconazole, 196t
Walking, 83, 84t-85t
Warfarin, 298-315
 advantages and disadvantages of, 326t
 antidote for, 326t
 bleeding risk and, 307-309, 309, 315
 catheter ablation and, 169
 indications for, 290, 292t
 cardioversion procedures, 134-135, 330, 336-337
 patients presenting with stroke, 335
 post-surgical AF, 339
 stroke prevention, 298-315
 interactions, 309-315
 cholesterol embolization, 315
 diet, 311-314, 314t
 drug interactions, 156t, 157t, 216, 240, 310-311, 312t-313t
 genetic polymorphism, 309-310
 herbal dietary supplements, 311, 314t
 hypermetabolism, 314
 pregnancy/lactation and, 315
 skin necrosis, 314
 sports activities, 315
 interruption of therapy, 340
 for stroke prevention, 298-315
 action mechanism, 305
 bleeding risk and, 307-309, 309
 cardioversion, therapy prior to, 330, 336-337
 dosing, 306
 efficacy, 298-304
 low-intensity warfarin, 301-302
 vs antiplatelet therapy, 302-304
 INR level and, 306-307, 308-309, 309
 major characteristics of, 304-315
 monitoring, 306-307, 307t
 pharmacokinetics, 305-306

Warfarin, for stroke prevention (*continued*)
 primary prevention, 298-300
 secondary prevention, 300-301
 vs dabigatran, 318-322, 319, 320t
Watchman device, 342, 343, 344-347, 344
Weight loss, 81-83
WOEST trial, 341
Wolff-Parkinson-White (WPW) syndrome, 56, 66, 272-273
 contraindications in, 260, 272
Women's Health Initiative Study, 100
Women's Health Study, 55, 99
WPW syndrome. See *Wolff-Parkinson-White syndrome*.

X-ray, chest, 69, 71t, 75

Young patients, 127, 127t, 192
 with AF and valvular heart disease, 125
 Cox-Maze procedure and, 185